http://rdf.ncbi.nlm.nih.gov/pubchem/reference/25108906

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Intramural
endingPage 131
issn 2326-5205
2326-5191
issueIdentifier 1
pageRange 121-131
publicationName Arthritis & rheumatology (Hoboken, N.J.)
startingPage 121
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_199db1bef4b0308c0639203aa0befa4f
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_ca0b45962a5a62ef43f07123284f7022
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_140d531fe45484d8a77a2a7c03509aa8
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_64a95886a98565ee65babf902e056a15
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_7c20eb8dd553906d2bb528903b4f09e0
bibliographicCitation Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon M, Parikh SV, Pendergraft WF, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis Rheumatol. 2021 Jan;73(1):121–31. PMID: 32755035; PMCID: PMC7839443.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_af65e71987d545bd3b472e172d9df73f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0098-1083
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b7732473559fed82b792921558472550
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d7810492151f235d5eb7bf828f840ef3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8440-8702
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_398bfd550516e35f6d3225d7b4f91c00
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_53c257902f2cea7033558c32ecec8017
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5dd990668d002fdfb88304a98694892d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3250-3804
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_29bb7221106d6bb12faa7953e73d0956
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7dcaa7aaa79109f0ff957791ed740721
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3cbb3f4ec13837b7d035ee8440ba0206
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_281639b00d06cc17ccd7b89768575cbc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4a29c275b8c8397ee900b99f235a187c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0d52872e16683a530a5c0503d33a3172
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9fa2b4067ab54d3e6442d3c7f7e22118
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-8350-3428
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_86c26a713589830820b0432d458c9213
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2361-0787
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9f158f1b0dd78efcd71424bb1495984
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_367d49c9ed135ab5d6ac26d31be7ea82
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9005-1690
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_07c71b9081c65637b3b475ace1c7a27a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e4469df2a6952103c50cc150f7b0ad13
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0df83ce445948924c643c85709e5f08d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1180a1aa5a691cddf220485e8ab5dd73
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9877cbec1015d340b530d9185d9a68cb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd7ab1988f5846bce818f502ed27d3a7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_510dffd0988e46b26989380df536d72c
date 202012
identifier https://pubmed.ncbi.nlm.nih.gov/32755035
https://pubmed.ncbi.nlm.nih.gov/PMC7839443
https://doi.org/10.1002/art.41466
isPartOf https://portal.issn.org/resource/ISSN/2326-5191
https://portal.issn.org/resource/ISSN/2326-5205
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/42112
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
discusses http://id.nlm.nih.gov/mesh/M0244307
http://id.nlm.nih.gov/mesh/M0500056
http://id.nlm.nih.gov/mesh/M0005485
http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0011171
http://id.nlm.nih.gov/mesh/M0011157
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D008181Q000188
http://id.nlm.nih.gov/mesh/D003520Q000627
http://id.nlm.nih.gov/mesh/D000069283Q000627
http://id.nlm.nih.gov/mesh/D061067Q000627
http://id.nlm.nih.gov/mesh/D007166Q000627
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D007155Q000627
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D055815
http://id.nlm.nih.gov/mesh/D004359
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8371
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907

Showing number of triples: 1 to 75 of 75.